Current Report Filing (8-k)
June 07 2017 - 12:19PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act
of 1934
Date of Report (Date of earliest event reported)
June 5,
2017
LEXARIA BIOSCIENCE CORP.
(Exact name of registrant as specified in its charter)
Nevada
|
000-52138
|
20-2000871
|
(State or other jurisdiction of
|
(Commission File Number)
|
(IRS Employer
|
incorporation)
|
|
Identification No.)
|
156 Valleyview Road, Kelowna, BC Canada
|
V1X 3M4
|
(Address of principal executive offices)
|
(Zip Code)
|
|
|
Registrants telephone number, including area code
|
(250) 765-6424
|
N/A
(Former name or former address, if
changed since last report.)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ] Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a -12)
[ ] Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[
] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e -4(c))
Item 3.02
Unregistered Sales of Equity Securities
On January 26, 2017 Lexaria Bioscience Corp. (the Company or
Lexaria) has announced it has received US$1,540 for the exercise of 11,000
existing warrants prices at US$0.14. The Company has also settled debt of
US$12,000 through the issuance of 35,294 shares at a deemed price of US$0.34.
200,000 stock options have been granted to Mr. Spissinger with an exercise price
of US$0.37. No commissions or placement fees have been paid related to the funds
received from this warrant exercise. Proceeds will be used for general corporate
purposes.
The securities referred to herein will not be or have not
been registered under the United States Securities Act of 1933, as amended, and
may not be offered or sold in the United States absent registration or an
applicable exemption from registration requirements.
- 2 -
Item 5.02. Departure of
Directors or Principal Officers; Election of Directors; Appointment of
Principal
Effective June 1, 2017, Allan Spissinger was appointed the new
acting CFO, Secretary and Treasurer. Allan Spissinger was involved in the
information technologies (IT) sector for more than 10 years working on corporate
IT infrastructure and software development projects before focusing on finance
and accounting. Allan joined the audit and assurance practice of
PricewaterouseCoopers (PwC) obtaining his Chartered Professional Accountant
(CPA) designation by working primarily in the public company space on financial
reporting and Sarbanes-Oxley (SOX) compliance in sectors including resources,
manufacturing and technologies.
Allan has managed private businesses for 20 years before
joining Lexaria in September 2014 as its corporate controller and is intimately
familiar with its operations, procedures and controls.
Item 7.01
Regulation FD Disclosure
A copy of the news release announcing that Lexaria has
appointed Allan Spissinger as the new acting CFO, Secretary and Treasury is
filed as exhibit 99.1 to this current report and is hereby incorporated by
reference.
Item 9.01
Financial Statements and Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
LEXARIA BIOSCIENCE CORP.
/s/ Chris
Bunka
|
|
Chris Bunka
|
|
CEO, Principal Executive Officer
|
|
|
|
Date: June 5, 2017
|
|